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ABSTRACT
Background: Immunomodulatory therapy has been recently introduced for the management of asthma.
Suplatast tosilate (ST), a new immune-modifying drug, is known to improve the airway function by inhibiting the
release of Th-2 cytokines. However, its efficacy as a controller listed in the guideline, Global Initiative for
Asthma 2005 has not been established. In this study we investigated the role of ST in leukotriene receptor an-
tagonist (LTRA) non-responders with mild-to-moderate persistent asthma before initiating corticosteroids inha-
lation therapy.
Methods: This was a prospective open-level clinical trial. LTRAs was given to 41 patients with asthma for 4
weeks and clinical efficacy was assessed using daily symptom scores. The 10 patients, aged 2.5―8.5 years,
who failed to show clinical improvement, were defined as LTRA non-responders. After a 1-week washout pe-
riod, the efficacy of ST was investigated and compared with LTRA non-responders for the following 4 weeks.
Results: LTRA non-responders showed a significant improvement in the average symptom score, peak expi-
ratory flow, use of rescue medication and the proportion of symptom-free days with ST therapy.
Conclusions: ST is a good choice for patients who have failed to respond to LTRAs. ST should therefore be
added to the list of treatment options for such patients.
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INTRODUCTION
Asthma is a chronic common disorder with an in-
creased incidence, especially among children. Treat-
ment for asthma has been designed to avoid irritating
symptoms and serious attacks, minimize the use of
rescue medication, to allow productive and physically
active lives, and to have optimal lung function. Daily
controller medications recommended in the Global
Initiative for Asthma for children with mild-to-
moderate persistent asthma, include inhaled gluco-
corticosteroids as a first-line therapy and sustained-
release theophylline, sodium cromoglycate, or LTRA
as treatment options.1
ST is a new drug expected to serve as a daily con-
troller alone, or to be used concurrently with inhaled
glucocorticosteroids. ST has a mechanism different
from any other therapy by blocking the allergic reac-
tion upstream via regulating the production of Th2-
cytokines.2 It also inhibits production of tissue- injur-
ing substances produced by mast cells and eosino-
phils.3 ST could therefore be considered as a new op-
tion in the stepwise approach toward corticosteroid
inhalation therapy, while also possibly reducing the
glucocorticosteroid dose when used concurrently.4
Health care professionals should always seek
methods to minimize treatment and medication in or-
der to minimize side effects while maintaining con-
trol. Inhaled glucocorticosteroids are anti-inflamm-
atory agents which are effective, long-term, preven-
tive medications in reducing asthma attacks. How-
ever, possible side effects such as adrenal suppres-
sion and growth delay, must always be considered, to
avoid hindering children’s growth and developmental
process.5 On the other hand, LTRAs are well-known
controller medications used solely or concurrently
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Fig. 1 A schematic drawing of the study design. After a 2-
week observation period, antileukotriene was given to pa-
tients for 4 weeks, during the screening period. The patients 
were classified as antileukotriene non-responders if their av-
erage symptom score over the first half (weeks 3 and 4) and 
second half (weeks 5 and 6) of the screening period were 
not significantly less compared to the observation period 
(weeks 1 and 2). After a 1-week wash-out period for LTRA, 
suplatast tosilate was administered to the antileukotriene 
non-responders for a 4-week trial period.
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with glucocorticosteroids. LTRA acts as an antagonist
for leukotrienes and inhibits bronchoconstriction and
inflammation.6 However, there are poor responders
to LTRA who require additional glucocorticosteroid
therapy or increased doses of glucocorticosteroids.7
This clinical trial was undertaken prospectively to
determine the role of ST as a second-line treatment in
LTRA non-responders with mild-to-moderate persis-
tent asthma, not yet treated by corticosteroid inhala-
tion therapy.
METHODS
PATIENTS
Men and women were eligible for the study and were
enrolled from June 2004 to May 2005 if they met the
following criteria: under 15 years of age but over 1
years-old; having a medical history of asthma and
classified as mild-to-moderately persistent by the
Global Initiative for Asthma; and did not respond to 4
weeks of LTRA therapy. Patients previously treated
with daily inhaled or oral corticosteroids were ex-
cluded. Written informed consent was obtained from
each patient or guardian and patient anonymity was
protected using documents and methods approved by
the ethical review board of Juntendo University Hos-
pital.
STUDY DESIGN
This 11-week study was approved by the institutional
review board (Fig. 1). The investigation was carried
out in accordance with the Declaration of Helsinki of
1995. Forty-one patients with mild-to-moderate persis-
tent asthma were observed during the screening pe-
riod to evaluate their responsiveness to LTRAs. After
a 2-week observation period, Pranlukast (7 mgkg
day in 2 separate doses) or Montelukast (4 mg, once
a day) was given during the 4-week screening period.
The use of theophylline and beta-agonist was contin-
ued if the patient had been receiving medication prior
to this study. Rescue medication was available
throughout the study period. Parents recorded the
daily symptom-score list,8 and the use of rescue medi-
cation and peak expiratory flow on a daily card. The
daily symptom-score list included the following 4
questions: 1) Did you notice your child coughing or
wheezing last night, 2) Was your child awake due to
coughing or wheezing last night, 3) Did you notice
coughing, wheezing, or shortness of breath today, 4)
Did these airway symptoms interfere with the activi-
ties of your child. The screening period was divided
into the first and second-second period each lasting
for 2 weeks. Patients were eligible if the average
symptom scores for both the first and second-second
half of the screening period failed to show a signifi-
cant decrease in comparison to that observed during
the observation period. A washout period of 1 week
was given, based on the pharmacokinetic data.9
After the 1-week washout period for LTRA, patients
entered the trial period. ST was administered at 6
mgkgday in 2 separate doses for 4 weeks. The par-
ents continued to record their daily card evaluations
throughout the study period.
ASSESSMENT OF EFFICACY AND SAFETY
The trial period was divided into the first and second-
second period, each lasting for 2 weeks. The outcome
measures included the average number of symptoms
per day, the number of symptom-free days, the peak
expiratory flow and the use of rescue medication for
the first and second-second half of the intervention
period. Patients were examined between 8 a.m. and 5
p.m., at the beginning and end of the observation,
screening and trial periods. Safety assessment was
made by examining adverse events and physical ex-
aminations.
STATISTICAL ANALYSES
All statistical tests were performed using two-sided
Student’s t-tests.
RESULTS
A total of 41 patients were eligible for enrollment.
The background characteristics and disposition of pa-
tients are shown in Table 1. Thirty-one patients were
classified as LTRA responders, from results showing
a significant decrease or improvement in the aver-
ages of symptom-scores over the first and second half
of the screening period compared to that of the ob-
servation period. The 10 patients who failed to show
any significant improvement in the average symptom-
score by LTRA administration, were classified as
LTRA non-responders and entered the trial period af-
ter a 1-week washout period.
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Fig. 2 a) Average symptom score, b) Proportion of 
symptom-free days, c) Average peak expiratory flow (n＝3) 
and d) Average use of rescue medication over the second 
half of the LTRA screening period (weeks 5 and 6) was com-
pared to the average during the first (weeks 8 and 9) and sec-
ond (weeks 10 and 11) half of the ST trial period. ＊ p＜0.05.
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Table 1 Baseline characteristics and patient disposition
LTRA 
non-responder
LTRA 
responder
1031Number of patients
60.0/40.071.0/29.0Male/Female (%) 
5.4±2.05.2±3.8Age (years) 
2.5―8.51.0―14.5Range (years) 
Type of LTRA (%) 
80.0/20.0100.0/0Pranlukast/Montelukast
Daily symptom-score
1.67±1.101.46±0.93Week 1―2
1.57±1.150.57±0.61 ＊ ＊Week 3―4
1.59±1.060.48±0.58 ＊ ＊Week 5―6
LTRA, leukotriene receptor antagonist. Data are expressed as 
the means±SD. ＊ p＜0.01 vs. week 1―2.
EFFICACY
The average symptom score over the second half of
the LTRA screening period was 1.59 (SD 1.06), while
the average scores in the first and second half of the
ST trial period were 0.16 (SD 0.32) and 0.32 (SD 0.28)
respectively. The symptom scores decreased signifi-
cantly in both phases of the ST trial period in com-
parison to the second half of the LTRA screening pe-
riod (paired Student’s t-test, p < 0.005, 0.004, respec-
tively; Fig. 2a).
The proportion of symptom-free days in the second
half of the LTRA screening period was 45.0% (SD
29.4) which increased significantly to 92.1% (SD 16.0)
and 83.6% (SD 18.8) respectively (paired t-test, p <
0.0005, 0.002; Fig. 2b) in the first and second half of
the ST trial period.
The average peak expiratory flow in the second
half of the LTRA screening period was 153.3 lminute
(SD 7.6) and those of the average in the first and sec-
ond half of the ST trial period were 168.3 lminute
(SD 16.1) and 170.0 lminute (SD 13.2) respectively.
In the second half of the ST trial period, a significant
increase was observed in comparison to the second
half of the LTRA screening period (n = 3, paired Stu-
dent’s t-test, p < 0.004; Fig. 2c).
The average use of rescue medication in the sec-
ond half of the LTRA screening period was 0.67
timesday (SD 0.43) and that of the average in the
first and second half of the ST trial period were 0.08
timesday (SD 0.15) and 0.13 timesday (SD 0.19) re-
spectively, thus revealing a significant decrease in
both phases (paired Student’s t-test, p < 0.006, 0.003;
Fig. 2d).
SAFETY
No adverse events were reported throughout the
study period and no significant abnormalities were
found in the physical examination findings.
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DISCUSSION
We set out to determine the role of ST in LTRA non-
responders with mild-to-moderate persistent asthma
before initiating corticosteroid inhalation therapy.
The results of this clinical trial demonstrated that
in patients who had not responded to LTRA, a signifi-
cant improvement occurred after initiation of ST re-
garding to symptom scores, the number of symptom-
free days, peak expiratory flow and use of rescue
medication.
Asthma is a chronic inflammation of the lower air-
ways accompanied by hypersensitivity and airway ob-
struction. Eosinophils play a major role in the allergic
inflammation of asthma contributing to tissue injury,
vascular leakage, mucus secretion, and airway
smooth muscle contraction.10 Eosinophils produce
tissue-injuring substances, such as major basic pro-
tein and eosinophil cationic protein (ECP), which
cause epithelial cell damage.11 Reactive oxygen spe-
cies are also released, resulting in airway tissue in-
jury12 and airway hypersensitivity. Eosinophils stimu-
late fibroblasts through TGF-β13 and GM-CSF,14 thus
promoting subepithelial collagen deposition, and
thickening and remodeling of the basement mem-
brane. Production of leukotriene C4 by eosinophils
also causes contraction of the bronchial smooth mus-
cle.15 Th2 cells have been implicated in the local infil-
tration and activation of eosinophils by the following
mechanism. First, Th2 cells produce IL-4 and 13
which upregulates the expression of cell adhesion
molecules in the vascular endothelial cells.16 Sec-
ondly, Th2-cell-mediated production of chemokines,
such as RANTES and eotaxin, is also involved in the
pathogenesis of eosinophilic infiltration.17 IL-5, also
released from Th2 cells, is involved in the activation
of eosinophils by promoting their growth, differentia-
tion and chemotaxis.18 Finally, GM-CSF produced by
Th2 cells induces eosinophilic elongation and de-
granulation resulting in tissue damage.19
Horiguchi et al.3 reported that 4 weeks of treat-
ment with ST reduced the peripheral blood eosino-
phil count, serum level of ECP, ECP level in induced
sputum, and inhibited airway hyper-responsiveness.
The difference in response to ST and LTRA in each
patient may depend upon the pathogenic mechanism
of asthma which is heterogeneous in each patient. ST
acts through a new concept of blocking the allergic
reaction by regulating the production of Th2-
cytokines, resulting in the inhibition of eosinophilic
migration and activation, to and at the inflammatory
site, while LTRA only partially blocks the role of
eosinophils in asthma.
Several studies have suggested that there are re-
sponders and nonresponders for both LTRA in addi-
tion to ST therapy. Approximately 20% of the patients
with mild-to-moderate asthma ranging from 3 to 15
years of age have been reported to be non-
responders to ST.20,21 Analyses of single-nucleotide
polymorphisms, gene expression, proteomes, and
metabonome have been conducted recently in the
hope of obtaining an effective basis for tailored medi-
cine. DNA sequence variants ALOX5 and LTC4S in
the leukotriene C (4) synthase genotype is predictive
of the clinical response to LTRA.22,23 Routinely-
measured laboratory parameters, such as the per-
centage of eosinophils and the basophil counts are
also good candidates for predicting the response to
ST.24 A combination of several predictors may serve
as an indicator for choosing the type of anti-allergic
agent to meet the individual needs of all patients and
obtain the best effect for each treatment.
Further studies are needed to test the efficacy of
ST as a first-line treatment for asthma, since the effec-
tiveness of early intervention using ST can expect to
suppress the allergic march. Yoshihara reported that
ST given at the food allergy stage, several months af-
ter birth, decreased the eosinophil count and in-
creased the Th1Th2 ratio, suggesting that it was
useful in the primary prevention of atopic asthma.25
On the other hand, the add-on effects of ST in pa-
tients treated with various doses of inhaled corti-
costeroids was reported to improve pulmonary func-
tion.4,26 Moreover, a steroid sparing effect was ob-
served in patients taking high doses of corticoster-
oids (1500 μday) to control symptoms in a double-
blind, randomized study by Tamaoki et al.4
The most recent guidelines for the diagnosis and
treatment of asthma recommend a low-to-medium
dose of glucocorticosteroids for mild-to-moderate per-
sistent patients. The option to be used solely or con-
currently with inhaled glucocorticosteroids are sus-
tained release theophylline, long acting beta-agonist,
sodium cromoglycate and LTRA. The results from
our study indicate that ST should be added to the list
of treatment options as it could be a good alternative
for patients who have failed to respond to LTRA.
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